Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Triamcinolone Acetonide for Vitreous Visualization During Vitrectomy
CTR20210035Phase 3Completed
- Sponsor
- Wakamoto Pharmaceutical
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of triamcinolone acetonide in diabetic retinopathy (DR), Vein occlusion (RVO), Retinal periphlebitis, vitreomacular traction (VMT), Proliferative Vitreoretinopathy (PVR), sponsored by Wakamoto Pharmaceutical. Started Jan 2021; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic retinopathy (DR)Vein occlusion (RVO)Retinal periphlebitisvitreomacular traction (VMT)Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on CTR20210035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210035.